Protein levels of FLT3, BCL2, and MCL1 were determined in AML cells treated with HSP90 inhibitor PU-H71, MCL1 inhibitor S63845, or BCL2 inhibitor venetoclax. Here, MCL1 is linked to acute myeloid leukemia.